Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XmAb24306 + daratumumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
XmAb24306 + daratumumab is a combination investigational therapy for relapsed or refractory multiple myeloma. **XmAb24306** (also called efbalropendekin alfa or RG6323) is a recombinant, half-life-extended IL-15/IL-15 receptor alpha heterodimer Fc fusion protein engineered to stimulate immune effector cells, especially natural killer (NK) cells, enhancing both their direct cytotoxic and antibody-dependent cellular cytotoxicity (ADCC). **Daratumumab** is a human monoclonal antibody targeting CD38, inducing ADCC and direct cytotoxicity against multiple myeloma cells, but it can also cause depletion (fratricide) of CD38-positive NK cells. Preclinical data show that XmAb24306, when combined with daratumumab, further boosts NK cell-mediated cytotoxicity against myeloma cells, even at low effector-to-target ratios, despite increased NK cell fratricide. This combination was studied in Phase 1 clinical trials for safety and pharmacokinetics in relapsed/refractory multiple myeloma patients.
- Other names
- efbalropendekin alfaRG6323RG-6323RG 6323
02
Targets
IL2RB (IL-2 receptor beta chain)CD38 (Cluster of Differentiation 38)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on XmAb24306 + daratumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XmAb24306 + daratumumab.